1. Scrip
  2. >>New Products

Novartis’ Entresto Faces Challenge From Natco In India

 
• By Anju Ghangurde

Natco has launched a cut-price version of sacubitril/valsartan (Novartis' Entresto) on the Indian market and is also believed to have opposed the patent for the heart failure therapy.

Indian currency
ENTRESTO FACES A CHALLENGE IN INDIA

Could Novartis AG be heading for another tough patent battle in India? It may be too early to predict how things will play out, but Natco Pharma Ltd.’s cut-price version of Novartis’ heart failure therapy Entresto (sacubitril/valsartan) has just made its debut on the Indian market, in what appears to be an “at-risk” launch.

The Hyderabad-based company said that it had launched Valsac (valsartan-sacubitril) tablet at an “affordable price”- the 50mg and 100mg strengths...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Merck & Co.’s RSV Antibody Approved In US In Time To Compete With Blockbuster Beyfortus

 
• By Mandy Jackson

The US FDA approved Merck’s Enflonsia (clesrovimab) to prevent RSV in newborns and infants on the same day Sanofi assured that it would ship Beyfortus in time for the 2025-2026 RSV season.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

Merck & Co.’s Enlicitide Poised To Be First Oral PCSK9 Inhibitor To Market

 
• By Jessica Merrill

The company announced positive data from two Phase III trials testing the cholesterol-lowering medicine.